• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALUNG TECHNOLOGIES, INC. HEMOLUNG RAS; EXTRACORPOREAL SYSTEM FOR CARBON DIOXIDE REMOVAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALUNG TECHNOLOGIES, INC. HEMOLUNG RAS; EXTRACORPOREAL SYSTEM FOR CARBON DIOXIDE REMOVAL Back to Search Results
Model Number HL-CR4-01-000
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Thrombocytopenia (4431)
Event Date 03/07/2021
Event Type  Injury  
Manufacturer Narrative
Patient information was not provided.Alung technologies, inc.Manufactures the hemolung ras and catheter.The incident occurred in louisville, kentucky.Alung technologies, inc.Received a report of a patient experiencing thrombocytopenia during therapy.Therapy was provided as intended.Medical intervention was required by changing the medication administered from heparin to argatroban.The data log was received and reviewed by clinical and software engineering staff.The co2 removal and blood flow graphs show that therapy was provided as intended.As indicated within this case, therapy was ended due to a probable circuit occlusion.Patient therapy was already planned to end.No capa was opened because of this event.Thrombocytopenia is a known potential complication associated with use of extracorporeal therapy.Review of the data log shows that therapy was provided as intended.Alung technologies, inc.Will continue to monitor any issues as they are reported.This mdr is being filed in response to a retrospective view of all alung technologies, inc.Complaints, which identified that the reporting decision for this complaint was not correct.This mdr is being filed retrospectively to correct the error in the reporting decision.
 
Event Description
Alung technologies, inc.Received a report of a patient experiencing thrombocytopenia during hemolung therapy.Therapy was provided as intended.Medical intervention was required by changing the medication administered from heparin to argatroban.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
HEMOLUNG RAS
Type of Device
EXTRACORPOREAL SYSTEM FOR CARBON DIOXIDE REMOVAL
Manufacturer (Section D)
ALUNG TECHNOLOGIES, INC.
2500 jane st
suite 1
pittsburgh PA 15203
Manufacturer Contact
ryan coyle
2500 jane st
suite 1
pittsburgh, PA 15203
MDR Report Key16211937
MDR Text Key307765389
Report Number3009763347-2023-00093
Device Sequence Number1
Product Code QOH
UDI-Device Identifier00850046004346
UDI-Public(01)00850046004346(17)180601
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
DEN210006
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 01/19/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/19/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberHL-CR4-01-000
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/17/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/01/2018
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Life Threatening;
-
-